9HUL
 
 | | Crystal structure of human GSK3b in complex with ARN25423 | | 分子名称: | Glycogen synthase kinase-3 beta, ~{N}-[3-[4-[2,3-bis(chloranyl)phenyl]piperazin-1-yl]propyl]-2-oxidanylidene-6-pyridin-3-yl-3~{H}-benzimidazole-1-carboxamide | | 著者 | Dalle Vedove, A, Di Martino, R.M.C, Storici, P, Girotto, S, Cavalli, A, Bottegoni, G. | | 登録日 | 2024-12-23 | | 公開日 | 2025-07-23 | | 実験手法 | X-RAY DIFFRACTION (2.9 Å) | | 主引用文献 | Rational optimization of D3R/GSK-3 beta dual target-directed ligands as potential treatment for bipolar disorder: Design, synthesis, X-ray crystallography, molecular dynamics simulations, in vitro ADME, and in vivo pharmacokinetic studies.
Eur.J.Med.Chem., 297, 2025
|
|
9HUK
 | | Crystal structure of human GSK3b in complex with ARN24161 | | 分子名称: | Glycogen synthase kinase-3 beta, ~{N}-[4-[4-[2,3-bis(chloranyl)phenyl]piperazin-1-yl]butyl]-2-oxidanylidene-6-pyridin-3-yl-3~{H}-benzimidazole-1-carboxamide | | 著者 | Dalle Vedove, A, Di Martino, R.M.C, Storici, P, Girotto, S, Cavalli, A, Bottegoni, G. | | 登録日 | 2024-12-23 | | 公開日 | 2025-07-23 | | 実験手法 | X-RAY DIFFRACTION (3.5 Å) | | 主引用文献 | Rational optimization of D3R/GSK-3 beta dual target-directed ligands as potential treatment for bipolar disorder: Design, synthesis, X-ray crystallography, molecular dynamics simulations, in vitro ADME, and in vivo pharmacokinetic studies.
Eur.J.Med.Chem., 297, 2025
|
|
9HV3
 | | Crystal structure of human GSK3b in complex with ARN25657 | | 分子名称: | 2-oxidanylidene-~{N}-[3-(4-phenylpiperazin-1-yl)propyl]-6-pyridin-3-yl-3~{H}-benzimidazole-1-carboxamide, Glycogen synthase kinase-3 beta | | 著者 | Dalle Vedove, A, Di Martino, R.M.C, Storici, P, Girotto, S, Cavalli, A, Bottegoni, G. | | 登録日 | 2024-12-24 | | 公開日 | 2025-07-23 | | 実験手法 | X-RAY DIFFRACTION (2.9 Å) | | 主引用文献 | Rational optimization of D3R/GSK-3 beta dual target-directed ligands as potential treatment for bipolar disorder: Design, synthesis, X-ray crystallography, molecular dynamics simulations, in vitro ADME, and in vivo pharmacokinetic studies.
Eur.J.Med.Chem., 297, 2025
|
|
